IL-6 plays a critical role in the expansion and differentiation of tumor cells [13,14] and can also modulate the tumor’s therapeutic resistance, such as multidrug resistance (MDR) [15], whose engagement triggers the activation of JAK and the downstream effectors STAT3, SHP-2/Ras, and PI3K/Akt [16]. This evidence concerns the gene PTPN11 and neoplasm.